Methamphetamine antibody (Cy5.5)

Catalog No. ABIN677293

This Rabbit Polyclonal antibody specifically detects Methamphetamine in WB, IF (cc), IF (p). It exhibits reactivity toward .

Quick Overview for Methamphetamine antibody (Cy5.5) (ABIN677293)

Target: Methamphetamine (M-Amp)

Reactivity: Please inquire

Host: Rabbit

Clonality: Polyclonal

Conjugate: This Methamphetamine antibody is conjugated to Cy5.5

Application: Western Blotting (WB), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p))

Product Details anti-Methamphetamine Antibody (Cy5.5)

Cross-Reactivity (Details): Methamphetamine

Purification: Purified by Protein A.

Immunogen: KLH conjugated to Methamphetamine

Isotype: IgG

Application Details

Application Notes: IF(IHC-P) 1:50-200

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Expiry Date: 12 months

Target Details for Methamphetamine

Target: Methamphetamine (M-Amp)

Alternative Name: Methamphetamine

Target Type: Chemical

Background:

Synonyms: d-Desoxyephedrine hydrochloride, d-N, -Dimethylphenethylamine hydrochloride, Methylamphetamine hydrochloride.

Background: Methamphetamine (METH) is closely related chemically to amphetamine (AMPH). METH is a potent central nervous system stimulant with additional peripheral sympathomimetic effects. METH and AMPH have been used clinically in the treatment of obesity, minimal brain dysfunction, narcolepsy, depression and to counter fatigue. They are also subjected to widespread abuse. METH is an indirect agonists. It causes the release of newly synthesized norepinephrine and dopamine and it blocks the re uptake of these transmitters from the synapse. This can lead to an increase in the concentration of catecholamines in the synapse as well as an overall increase in catecholaminergic activity in the brain. The mechanism of METH induced neurotoxicity for all monoaminergic cell types may lie primarily with the dopaminergic system in the striatum. It may also lie with the interaction between METH induced release of dopamine and its ability to inhibit monoamine oxidase.